OraSure Technologies, Inc. (OSUR)
OSUR Stock Price Chart
Explore OraSure Technologies, Inc. interactive price chart. Choose custom timeframes to analyze OSUR price movements and trends.
OSUR Company Profile
Discover essential business fundamentals and corporate details for OraSure Technologies, Inc. (OSUR) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Instruments & Supplies
IPO Date
17 Nov 1986
Employees
501.00
Website
https://www.orasure.comCEO
Carrie Eglinton Manner
Description
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, Diagnostics and Molecular Solutions. The company's principal products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands; microbiome collection products; and GenoFIND genomics laboratory services. In addition, the company provides ORAcollect, RNA and OMNIgene, and RAL collection devices for use in connection with COVID-19 molecular testing; offers Colli-Pee collection device for the volumetric collection of first void urine; and manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the academic research and commercial applications, including ancestry, disease risk management, lifestyle, and animal testing. Further, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure Technologies, Inc. was incorporated in 2000 and is headquartered in Bethlehem, Pennsylvania.
OSUR Financial Timeline
Browse a chronological timeline of OraSure Technologies, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 May 2026
Upcoming earnings on 23 Feb 2026
Upcoming earnings on 5 Nov 2025
EPS estimate is -$0.14, while revenue estimate is $28.97M.
Earnings released on 5 Aug 2025
EPS came in at -$0.19 falling short of the estimated -$0.15 by -26.67%, while revenue for the quarter reached $31.24K , missing expectations by -8.03%.
Earnings released on 7 May 2025
EPS came in at -$0.18 falling short of the estimated -$0.15 by -20.00%, while revenue for the quarter reached $934.00K , missing expectations by -96.84%.
Earnings released on 25 Feb 2025
EPS came in at -$0.06 falling short of the estimated -$0.05 by -20.00%, while revenue for the quarter reached $37.45M , beating expectations by +1.87%.
Earnings released on 6 Nov 2024
EPS came in at -$0.01 falling short of the estimated -$0.01 by -22.10%, while revenue for the quarter reached $264.00K , missing expectations by -99.28%.
Earnings released on 6 Aug 2024
EPS came in at $0.07 surpassing the estimated $0.04 by +66.67%, while revenue for the quarter reached $54.34M , beating expectations by +4.23%.
Earnings released on 8 May 2024
EPS came in at $0.04 surpassing the estimated -$0.01 by +766.67%, while revenue for the quarter reached $54.13M , beating expectations by +3.90%.
Earnings released on 27 Feb 2024
EPS came in at $0.27 surpassing the estimated $0.09 by +200.00%, while revenue for the quarter reached $75.88M , beating expectations by +2.38%.
Earnings released on 7 Nov 2023
EPS came in at $0.27 surpassing the estimated $0.07 by +285.71%, while revenue for the quarter reached $89.19M , beating expectations by +18.98%.
Earnings released on 3 Aug 2023
EPS came in at -$0.07 falling short of the estimated -$0.06 by -16.67%, while revenue for the quarter reached $85.44M , beating expectations by +74.69%.
Earnings released on 10 May 2023
EPS came in at $0.37 surpassing the estimated $0.14 by +164.29%, while revenue for the quarter reached $154.96M , beating expectations by +22.43%.
Earnings released on 14 Feb 2023
EPS came in at $0.21 surpassing the estimated $0.01 by +2.20K%, while revenue for the quarter reached $123.08M , beating expectations by +26.75%.
Earnings released on 8 Nov 2022
EPS came in at $0.07 surpassing the estimated $0.02 by +274.93%, while revenue for the quarter reached $116.46M , beating expectations by +27.00%.
Earnings released on 9 Aug 2022
EPS came in at -$0.26 falling short of the estimated -$0.13 by -100.00%, while revenue for the quarter reached $80.23M , beating expectations by +14.77%.
Earnings released on 10 May 2022
EPS came in at -$0.28 falling short of the estimated -$0.14 by -100.00%, while revenue for the quarter reached $67.71M , beating expectations by +12.46%.
Earnings released on 23 Feb 2022
EPS came in at -$0.14 surpassing the estimated -$0.16 by +12.50%, while revenue for the quarter reached $63.57M , beating expectations by +2.61%.
Earnings released on 3 Nov 2021
EPS came in at -$0.21 falling short of the estimated -$0.05 by -320.00%, while revenue for the quarter reached $53.92M , beating expectations by +15.75%.
Earnings released on 3 Aug 2021
EPS came in at -$0.02 falling short of the estimated -$0.01 by -148.76%, while revenue for the quarter reached $57.61M , meeting expectations.
Earnings released on 5 May 2021
EPS came in at $0.05 surpassing the estimated $0.04 by +12.89%, while revenue for the quarter reached $58.58M , beating expectations by +2.78%.
Earnings released on 1 Mar 2021
EPS came in at $0.03 falling short of the estimated $0.07 by -57.14%, while revenue for the quarter reached $62.86M , beating expectations by +9.71%.
Earnings released on 4 Nov 2020
EPS came in at $0.01 surpassing the estimated -$0.07 by +114.29%, while revenue for the quarter reached $48.01M , missing expectations by -85.71%.
OSUR Stock Performance
Access detailed OSUR performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.